- Home
- JANX vs PCH Comparison
JANX vs PCH Comparison
Compare JANX & PCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JANX
- PCH
- Stock Information
- Founded
- JANX 2017
- PCH 1903
- Country
- JANX United States
- PCH United States
- Employees
- JANX 103
- PCH N/A
- Industry
- JANX Biotechnology: Pharmaceutical Preparations
- PCH Real Estate Investment Trusts
- Sector
- JANX Health Care
- PCH Real Estate
- Exchange
- JANX Nasdaq
- PCH Nasdaq
- Market Cap
- JANX 1.4B
- PCH 3.3B
- IPO Year
- JANX 2021
- PCH N/A
- Fundamental
- Price
- JANX $24.21
- PCH $40.93
- Analyst Decision
- JANX Strong Buy
- PCH Strong Buy
- Analyst Count
- JANX 11
- PCH 6
- Target Price
- JANX $76.55
- PCH $49.67
- AVG Volume (30 Days)
- JANX 586.6K
- PCH 459.3K
- Earning Date
- JANX 11-05-2025
- PCH 10-27-2025
- Dividend Yield
- JANX N/A
- PCH 4.46%
- EPS Growth
- JANX N/A
- PCH 15.06
- EPS
- JANX N/A
- PCH 0.53
- Revenue
- JANX $439,000.00
- PCH $1,056,523,000.00
- Revenue This Year
- JANX N/A
- PCH $4.42
- Revenue Next Year
- JANX $130.50
- PCH $3.61
- P/E Ratio
- JANX N/A
- PCH $76.19
- Revenue Growth
- JANX N/A
- PCH N/A
- 52 Week Low
- JANX $21.97
- PCH $36.82
- 52 Week High
- JANX $71.71
- PCH $48.12
- Technical
- Relative Strength Index (RSI)
- JANX 51.41
- PCH 45.45
- Support Level
- JANX $23.15
- PCH $40.26
- Resistance Level
- JANX $24.79
- PCH $41.68
- Average True Range (ATR)
- JANX 1.14
- PCH 0.98
- MACD
- JANX 0.04
- PCH -0.20
- Stochastic Oscillator
- JANX 56.60
- PCH 20.00
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
About PCH PotlatchDeltic Corporation
PotlatchDeltic Corp is a REIT that owns and manages forestland in Alabama, Arkansas, Idaho, Minnesota, and Mississippi. Potlach operates in three segments. The timberlands segment covers the planting and harvesting of trees, as well as the construction and maintenance of roads. The wood products segment manufactures and distributes lumber, plywood, and other wood products. The real estate segment covers the sales generated from company-owned timberlands, as well as commercial and residential properties. The timberlands and the wood product segments combined drive the majority of the company's revenue.